BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Viking Therapeutics’ Obesity Drug Trial Disappoints, But Long-Term Potential Remains
Viking Therapeutics’ Obesity Drug Trial Disappoints, But Long-Term Potential Remains
18
2
BTCCSquare news:
Viking Therapeutics faced market skepticism after revealing a 20% discontinuation rate due to adverse effects in its Phase 2 trial for oral obesity drug VK2735. The setback contrasts with competing therapies from Eli Lilly and Novo Nordisk, which demonstrated better tolerability profiles in late-stage trials.
Investors initially focused on the oral formulation's commercial potential, but safety concerns have shifted attention to the subcutaneous version's 2027 timeline. The stock's volatility reflects the biotech sector's high-risk, high-reward nature—where clinical setbacks create entry points for long-term believers.
By:
